ArticleScience (New York, N.Y.)2023
Oncogenic
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 51 citations in OpenAlex.
- ZC3H14 phosphorylation is required for nuclear speckle assembly during zygotic splicing activation in mice.EMBO reports · 2026Article
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- Targeting CDKs in the RNAPII transcription cycle.Nature reviews. Drug discovery · 2026Review
- The Role of Transcriptional and Atypical Cyclin-Dependent Protein Kinases in Melanoma.Cancers · 2026Review
- Regulation of RNA transcript elongation in metazoans and its relevance to disease.Nature reviews. Molecular cell biology · 2026Review
- Review
- Recurrent ZC3H18 mutations stabilize oncogenic endogenous retroviral RNA.Cell reports · 2026Article
- The competition between splicing and 3' processing shapes the human transcriptome.Genes & development · 2026Article
- Deciphering O‑GlcNAc-Dependent Signaling Via Integrated Proteomics and Phosphoproteomics.ACS omega · 2026Article
- Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage.Journal of cellular and molecular medicine · 2026Article
- The Emerging Role of Transcription-Associated Cyclin-Dependent Kinases in Gastrointestinal Tumors.Cancers · 2026Review
- DIS3 mutations enhance AID-driven translocations during B-cell activation, promoting transformation to multiple myeloma.Nature communications · 2026Article
- CDK13 drives clear cell renal carcinoma through METTL16-mediated mExperimental & molecular medicine · 2026Article
- Coordinating mRNA maturation: The U1 relay model.Molecular cell · 2026Review
- CDK10 suppresses nucleic acid sensors-mediated antitumor immunity.Nature cancer · 2026Article
- CDK12 and CDK13 in oncology: from RNA regulation to therapeutic targeting.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Highly Efficient Site-Specific and Cassette Mutagenesis of Plasmids Harboring GC-Rich Sequences.Cells · 2025Article
- A kinetic ruler controls mRNA poly(A) tail length.Genes & development · 2025Article
- CDK13-Related Disorder: Novel Insights From A Series of 27 Cases and Recommendations for Clinical Management.Clinical genetics · 2025Article
- Cancer-associated loss-of-function mutations in KCNQ1 enhance Wnt/β-catenin signalling disrupting epithelial homeostasis.Oncogene · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 9 institutions in 2 countries.
Megan L InscoStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.ORCID 0000-0002-6078-6506
Brian J AbrahamDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0001-8085-3027
Sara J DubburyThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-9881-6985
Ines H KaltheunerInstitute of Structural Biology, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0001-8450-4959
Sofia DustInstitute of Structural Biology, University of Bonn, 53127 Bonn, Germany.
Constance WuStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.ORCID 0000-0002-2996-1505
Kevin Y ChenStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.
David LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0003-0346-5033
Stanislav BellaousovUniversity of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
Anna M CoxStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.ORCID 0000-0001-9915-8876
Benjamin J E MartinDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-2296-6346
Tongwu ZhangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.ORCID 0000-0003-2124-2706
Calvin G LudwigStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.ORCID 0000-0002-1938-4273
Tania FaboStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.ORCID 0000-0002-8987-0672
Rodsy ModhurimaStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.
Dakarai E EsgdailleUniversity of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.ORCID 0000-0002-9388-9421
Telmo HenriquesDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Kevin M BrownDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.ORCID 0000-0002-8558-6711
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.ORCID 0000-0002-2324-3393
Matthias GeyerInstitute of Structural Biology, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0002-7718-5002
Karen AdelmanDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-5364-334X
Phillip A SharpThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-1465-1691
Richard A YoungDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0001-8855-8647
Paul L BoutzUniversity of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.ORCID 0000-0003-0788-3136
Leonard I ZonStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.ORCID 0000-0003-0860-926X
Howard Hughes Medical Institute · USHarvard University · USNational Cancer Institute · USUniversity of Bonn · DEUniversity of Rochester · USMassachusetts Institute of Technology · USDana-Farber Cancer Institute · USSt. Jude Children's Research Hospital · USWhitehead Institute for Biomedical Research · US
Funding
USE OF RETROVIRUS PROMOTER TRAP VECTORS TO IDENTIFY ONCOGENES AND ANTI-ONCOGENESP01CA042063 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI JACKS, TYLER E. · 1986 to 2021
$30.5MTranscriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 2013 to 2026
$25.3MREGULATION OF MRNA PROCESSINGR01GM034277 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHARP, PHILLIP A · 1985 to 2021
$8.0MCancer Biology in the ZebrafishR01CA103846 · NCI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 2003 to 2022
$7.5MTraining Program in Molecular HematologyT32HL116324 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI NANCY BERLINER · 2013 to 2026
$7.4MStress and Proliferation States Impact MicroRNA-Mediated Regulation in CancerR01CA133404 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHARP, PHILLIP A · 2008 to 2017
$4.6MTranscriptional regulation in mammalian cellsR35GM144283 · NIGMS · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI RICHARD YOUNG · 2022 to 2026
$4.0MTraining in Wellness and Resiliency at the University of Rochester Medical Center and College of Arts, Sciences & EngineeringT32GM135134 · NIGMS · UNIVERSITY OF ROCHESTER · PI Jeffrey J Hayes, Lynne E Maquat · 2020 to 2026
$2.9MGenomics-based approaches to understanding mechanistic alterations of spliceosome function in disease statesR01GM141544 · NIGMS · UNIVERSITY OF ROCHESTER · PI BOUTZ, PAUL LAWRENCE · 2021 to 2025
$1.6MInvestigating Transcriptional Elongation and Nuclear RNA Surveillance in MelanomaK08CA248727 · NCI · DANA-FARBER CANCER INST · PI INSCO, MEGAN LEIGH · 2021 to 2025
$980kNCI NIH HHS K08 CA248727NCI NIH HHS P01 CA042063NCI NIH HHS P01 CA163222NCI NIH HHS R01 CA103846NCI NIH HHS R01 CA133404NHLBI NIH HHS T32 HL116324NIGMS NIH HHS R01 GM034277NIGMS NIH HHS R01 GM141544NIGMS NIH HHS R35 GM144283NIGMS NIH HHS T32 GM135134
Abstract
RNA surveillance pathways detect and degrade defective transcripts to ensure RNA fidelity. We found that disrupted nuclear RNA surveillance is oncogenic. Cyclin-dependent kinase 13 (
Indexed as
CarcinogensCDC2 Protein KinaseMelanomaRNA, NuclearRNA StabilitySkin NeoplasmsAnimalsHumansMutationZebrafishCarcinogensCDC2 Protein KinaseCDK13 protein, humanRNA, Nuclear
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.